<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319940</url>
  </required_header>
  <id_info>
    <org_study_id>20160323</org_study_id>
    <nct_id>NCT03319940</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with
      Small Cell Lung Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757
      administered as a short term intravenous (IV) infusion in subjects with small cell lung
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2017</start_date>
  <completion_date type="Anticipated">April 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 in subjects with Small Cell Lung Cancer. The dose exploration phase of the study will estimate the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of AMG 757. This will be followed by dose expansion phase to confirm the MTD and to obtain further safety and efficacy data. Alternative dosing schedule(s) may be explored based on emerging pharmacokinetic and safety data</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The patient, investigator, investigative staff, medical monitor and care provider will not be masked for the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of dose limiting toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Number of subjects who experience dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of treatment-emergent and treatment-related adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Number of subjects who experience treatment-emergent and treatment-related adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>AMG 757 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 757</intervention_name>
    <description>AMG 757</description>
    <arm_group_label>AMG 757 Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old at the time of signing the informed consent

          -  Histologically or cytologically confirmed Small Cell Lung Cancer (SCLC)

               -  Part A: RR SCLC who progressed or recurred following platinum-based chemotherapy;

               -  Part B: ED SCLC with ongoing clinical benefit (stable disease [SD], partial
                  response [PR], or complete response [CR]) following no more than 4 cycles of
                  first-line platinum-based chemotherapy with the last dose of chemotherapy ≥ 28
                  days prior to the study day 1 (first-line consolidation setting).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Minimum life expectancy of 12 weeks

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Major surgery within 28 days of first dose AMG 757

          -  Myocardial infarction and/or symptomatic congestive heart failure (New York Heart
             Association &gt; class II) within 12 months of first dose of AMG 757

          -  History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12
             months of first dose of AMG 757

          -  Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials
             for management.

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

